- Home
- THTX vs EPIX Comparison
THTX vs EPIX Comparison
Compare THTX & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THTX
- EPIX
- Stock Information
- Founded
- THTX 1993
- EPIX 2009
- Country
- THTX Canada
- EPIX Canada
- Employees
- THTX N/A
- EPIX N/A
- Industry
- THTX Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- THTX Health Care
- EPIX Health Care
- Exchange
- THTX Nasdaq
- EPIX Nasdaq
- Market Cap
- THTX 93.3M
- EPIX 77.2M
- IPO Year
- THTX N/A
- EPIX N/A
- Fundamental
- Price
- THTX $1.48
- EPIX $1.68
- Analyst Decision
- THTX Hold
- EPIX Hold
- Analyst Count
- THTX 1
- EPIX 3
- Target Price
- THTX N/A
- EPIX $2.00
- AVG Volume (30 Days)
- THTX 108.7K
- EPIX 216.4K
- Earning Date
- THTX 02-19-2025
- EPIX 02-11-2025
- Dividend Yield
- THTX N/A
- EPIX N/A
- EPS Growth
- THTX N/A
- EPIX N/A
- EPS
- THTX N/A
- EPIX N/A
- Revenue
- THTX $84,316,000.00
- EPIX N/A
- Revenue This Year
- THTX $5.78
- EPIX N/A
- Revenue Next Year
- THTX $2.47
- EPIX N/A
- P/E Ratio
- THTX N/A
- EPIX N/A
- Revenue Growth
- THTX 5.75
- EPIX N/A
- 52 Week Low
- THTX $1.08
- EPIX $1.40
- 52 Week High
- THTX $2.18
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- THTX 36.81
- EPIX 38.58
- Support Level
- THTX $1.42
- EPIX $1.69
- Resistance Level
- THTX $1.76
- EPIX $1.79
- Average True Range (ATR)
- THTX 0.09
- EPIX 0.07
- MACD
- THTX -0.05
- EPIX 0.01
- Stochastic Oscillator
- THTX 17.63
- EPIX 11.11
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.